Eli Lilly expanded its metabolic pipeline by signing a multiyear discovery and exclusive worldwide license with Nimbus Therapeutics focused on an oral obesity program, with total value potential of approximately $1.3 billion. Lilly committed about $55 million in upfront and near-term payments tied to milestones and rights to candidates discovered under the deal. Nimbus will apply its structure-based computational chemistry engine to identify small-molecule oral candidates aimed at obesity and related metabolic diseases. The collaboration builds on prior Lilly–Nimbus work and underscores Big Pharma’s continued appetite for oral alternatives in the obesity space. For investors and competitors, the pact signals Lilly’s intent to broaden non-injectable weight-loss options and validates Nimbus’ discovery platform as a commercial partner for large pharma.